McKesson Banks On Distribution Business Amid Pricing Woes
Zacks Investment Research | Aug 15, 2017 09:49PM ET
On Aug 14, we issued an updated research report on San Francisco, CA-based McKesson Corporation (NYSE:MCK) , a health care services and information technology company. McKesson posted disappointing results in first-quarter fiscal 2018, wherein adjusted earnings and revenues missed the Zacks Consensus Estimate. The company currently has a Zacks Rank #3 (Hold).
The quarter saw strong performance by the Distribution Solutions segment. The segment is expected to keep up its performance in fiscal 2018 despite weak pricing trends and customer consolidation. To boost growth, the company recently acquired CoverMyMeds for approximately $1.1 billion.
Coming to guidance, the Distribution Solutions business revenue growth is expected to witness robust growth on a year-over-year basis. The upside is expected to be driven by market growth and acquisitions.McKesson expects GAAP earnings per diluted share of $7.10-$9.00 for the fiscal ending Mar 31, 2018. Adjusted earnings for the same period are expected in the range of $11.80-$12.50 per diluted share.
On the flipside, pricing pressure in the independent retail pharmacy channel is a headwind. McKesson entered fiscal 2018 with an assumption of branded inflation in the mid-single digits and its first quarter slightly surpassed expectations.
McKesson has been witnessing increased price competition in the independent retail pharmacy channel, which eventually resulted in reduced volumes. The company continues to see a competitive market for selling generic pharmaceuticals in the U.S. However, McKesson expects to overcome the independent pharmacy sell-side pricing impact by the end of second-quarter fiscal 2018.
Furthermore, cutthroat competition in the niche markets, currency headwinds and reimbursement issues remain challenges.
Stock Performance and Estimate Revision Trend
Over the last three months, McKesson has been trading above the broader industry. The company has gained 5.1%, comparing favorably with the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.